PTC Therapeutics Inc (PTCT)
40.41
-0.06
(-0.15%)
USD |
NASDAQ |
Nov 04, 16:00
40.40
-0.02
(-0.04%)
After-Hours: 20:00
PTC Therapeutics Revenue (Quarterly): 186.70M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 186.70M |
| March 31, 2024 | 210.12M |
| December 31, 2023 | 307.06M |
| September 30, 2023 | 196.58M |
| June 30, 2023 | 213.81M |
| March 31, 2023 | 220.38M |
| December 31, 2022 | 167.41M |
| September 30, 2022 | 217.13M |
| June 30, 2022 | 165.53M |
| March 31, 2022 | 148.74M |
| December 31, 2021 | 165.23M |
| September 30, 2021 | 138.74M |
| June 30, 2021 | 116.68M |
| March 31, 2021 | 117.94M |
| December 31, 2020 | 118.86M |
| September 30, 2020 | 118.40M |
| June 30, 2020 | 75.24M |
| March 31, 2020 | 68.26M |
| December 31, 2019 | 96.46M |
| September 30, 2019 | 71.42M |
| June 30, 2019 | 85.52M |
| March 31, 2019 | 53.58M |
| December 31, 2018 | 86.34M |
| September 30, 2018 | 53.59M |
| June 30, 2018 | 68.74M |
| Date | Value |
|---|---|
| March 31, 2018 | 56.06M |
| December 31, 2017 | 78.03M |
| September 30, 2017 | 41.85M |
| June 30, 2017 | 47.96M |
| March 31, 2017 | 26.55M |
| December 31, 2016 | 25.19M |
| September 30, 2016 | 22.99M |
| June 30, 2016 | 15.63M |
| March 31, 2016 | 18.90M |
| December 31, 2015 | 12.73M |
| September 30, 2015 | 9.776M |
| June 30, 2015 | 6.774M |
| March 31, 2015 | 7.482M |
| December 31, 2014 | 13.88M |
| September 30, 2014 | 0.797M |
| June 30, 2014 | 1.418M |
| March 31, 2014 | 9.147M |
| December 31, 2013 | 7.301M |
| September 30, 2013 | 15.46M |
| June 30, 2013 | 5.868M |
| March 31, 2013 | 6.072M |
| December 31, 2012 | 5.918M |
| September 30, 2012 | 6.043M |
| June 30, 2012 | 6.064M |
| March 31, 2012 | 10.75M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
68.26M
Minimum
Mar 2020
307.06M
Maximum
Dec 2023
160.49M
Average
165.23M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 17.70B |
| Vertex Pharmaceuticals Inc | 2.646B |
| BridgeBio Pharma Inc | 2.168M |
| Cassava Sciences Inc | -- |
| Crinetics Pharmaceuticals Inc | 0.399M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -99.18M |
| Total Expenses (Quarterly) | 220.06M |
| EPS Diluted (Quarterly) | -1.29 |
| Enterprise Value | 2.305B |
| Gross Profit Margin (Quarterly) | 91.68% |
| Profit Margin (Quarterly) | -53.12% |
| Earnings Yield | -15.61% |
| Normalized Earnings Yield | -11.02 |